Akebia Therapeutics News

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Yahoo Finance03:27

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Yahoo Finance03:06

Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations

Yahoo FinanceMay 10 21:19

Akebia Therapeutics(AKBA.US) Officer Sells US$31,050 in Common Stock

$Akebia Therapeutics(AKBA.US)$ Officer Burke Steven Keith sold 27,000 shares of common stock on Aug 25, 2023 at an average price of $1.15 for a total value of $31,050.Source: Announcement What is stat

Futu NewsMay 10 06:07

Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers

Seeking AlphaMay 9 22:00

Akebia Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.

Akebia Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.

BenzingaMay 9 20:24

Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M

07:14 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M

MT NewswiresMay 9 19:14

Akebia Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 19:07 · Announcements

Akebia Therapeutics Q1 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $32.607M Miss $46.087M Estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. The company reported quarterly sales of $32.607

BenzingaMay 9 19:04

Akebia Therapeutics 1Q Loss/Shr 9c >AKBA

Akebia Therapeutics 1Q Loss/Shr 9c >AKBA

Dow JonesMay 9 19:00

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on...

PR NewswireMay 2 20:30

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

Yahoo FinanceApr 28 22:23

Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)

TipRanksApr 26 19:50

Averoa Seeks EU Approval for Chronic Kidney Disease Drug

France-based Averoa filed a marketing authorization application to the European Medicines Agency for its AVA1014 drug to treat complications associated with chronic kidney disease. The biopharmaceutic

MT NewswiresApr 23 19:36

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersIN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) share

BenzingaApr 10 20:09

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

PR NewswireApr 3 04:05

12 Health Care Stocks Moving In Friday's Intraday Session

GainersAvalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASD

BenzingaMar 30 00:30

Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 29 00:29

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics with a Buy and raises the price target from $5 to $6.

Analyst UpgradesMar 29 00:20

Akebia Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 199.25% HC Wainwright & Co. $5 → $6 Maintains Buy 03/15/2024 149.38% HC Wainwright & Co. → $5 R

BenzingaMar 29 00:18